Dr. Oh's research interests include exploring the role of chemotherapy in both castration-resistant prostate cancer (CRPC) and localized high-risk prostate cancer. Dr. Oh is also interested in the role of secondary hormone therapies in the treatment of advanced prostate cancer.
A major research area for Dr. Oh has been the development and management of a prospective clinical database linked to blood and tissue banks for prostate cancer patients. His recent research efforts exploring this database have included characterization of the efficacy of various therapies in advanced prostate cancer (e.g. Xofigo, nilutamide, ketoconazole, vinorelbine, docetaxel, mitoxantrone), assessment of PSA doubling time as a prognostic and predictive factor, efficacy of hormonal therapy, assessment of testosterone as a marker for cancer outcome, prediction of relapse based on nutritional factors at diagnosis and autoantibody signatures, and assessment of pharmacogenomic patterns predicting Gleason score.
Don’t miss Dr. William K. Oh on Saturday, September 12, as well as so many other esteemed prostate cancer experts covering a wide variety of topics including; Chemotherapy, Xofigo, Bone Health, Immune Therapy, Seed Implant Radiation, Active Surveillance and managing the sexual side effects of treatment.